Literature DB >> 11396988

Restoration of calcium handling properties of adult cardiac myocytes from hypertrophied hearts.

A M Reilly1, S Petrou, R G Panchal, D A Williams.   

Abstract

Reductions in cardiac sarcoplasmic reticulum calcium-ATPase (Serca2a) levels are thought to underlie the prolonged calcium (Ca(2+)) transients and consequent reduced contractile performance seen in human cardiac hypertrophy and heart failure. In freshly isolated cardiac myocytes from rats with monocrotaline-induced right ventricular hypertrophy we found reduced sarcoplasmic reticulum Serca2a expression and prolonged Ca(2+)transients, characteristic of hypertrophic cardiac disease. Modulation of intracellular Ca(2+)levels, Ca(2+) kinetics or Ca(2+)sensitivity is the focus of many current therapeutic approaches to improve contractile performance in the hypertrophic or failing heart. However, the functional effects of increasing Serca2a expression on Ca(2+) handling properties in myocytes from an animal model of cardiac hypertrophy are largely unknown. Here, we describe enhancement of the deficient Ca(2+) handling properties evident in myocytes from hypertrophied hearts following adenoviral-mediated transfer of the human Serca2a gene to these myocytes. These results highlight the importance of Serca2a deficiencies in the hypertrophic phenotype of cardiac muscle and suggest a simple, effective approach for manipulation of normal cardiac function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396988     DOI: 10.1054/ceca.2001.0213

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  2 in total

1.  Response of non-failing hypertrophic rat hearts to prostaglandin F2α.

Authors:  Anna Maria Krstic; Sarbjot Kaur; Marie-Louise Ward
Journal:  Curr Res Physiol       Date:  2019-12-27

Review 2.  CircRNA ITCH: Insight Into Its Role and Clinical Application Prospect in Tumor and Non-Tumor Diseases.

Authors:  Tong Liu; Tao Huang; Mei Shang; Gang Han
Journal:  Front Genet       Date:  2022-07-15       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.